shareholdersunite.com

• After divesting its surgical products, the company has two main businesses left, the ESS and IGB business.
• We are quite optimistic about their ESS business as the company has just introduced a much better version of its OverStitch.
• However, its intragastric balloons’ business, good for one-third of revenues could be under threat from competition developing adjustable balloons.
• Company finances are also pretty bleak.

Source: A Serious Threat Is Emerging To Apollo Endosurgery’s IGB Business – Apollo Endosurgery, Inc. (NASDAQ:APEN) | Seeking Alpha